The goal of the Functional Genomics Core (FGC) is to provide a comprehensive, integrated approach to genomics research for Cancer Center investigators. Presently, the FGC provides a range of Microarray and Data Analysis Services. The microarray gene expression profiling service is based on the Affymetrix oligonucleotide array platform of GeneChips. Basic and advanced data analysis is provided by biostatisticians and bioinformaticists in conjunction with the Biomedical Informatics Core. The FGC is currently undergoing expansion to provide two new major services, RNAi-based technology and genotyping. The former allows functional analyses of genes using approaches such as siRNA, and latter provides moderate-throughput SNP and DMA methylation analyses. All of the FGC services are provided by highly experienced Core Managers with extensive expertise in their areas of specialization. Cohesiveness and synergy among all of the FGC components are provided by the Scientific Director, who leads regular meetings with all Core Managers to discuss assay development, data analysis, trouble-shooting, integration, and new techniques. The Core Managers provide advice to investigators on experimental design prior to laboratory and clinical studies, assay development and quality control during the studies and interpretation of data generated by the Core. This """"""""one-stop shopping"""""""" approach makes functional genomics research more broadly accessible to Cancer Center investigators. Thus, the FGC provides advanced technologies and support for basic, clinical and population studies that enhance functional genomics research and collaborations across all COHCCC programs. During the prior 12-month reporting period, the FGC was used by 14 Cancer Center members from all 5 Research Programs;peer-reviewed usage represented 76% of the total. The proposed total annual budget is $339,788, representing 39% institutional support, 18% user fees, 16% other, and 27% ($91,000) requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-26
Application #
8182245
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-12-01
Budget End
2009-11-30
Support Year
26
Fiscal Year
2009
Total Cost
$30,336
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Salgia, Ravi; Kulkarni, Prakash; Gill, Prakash S (2018) EphB4: A promising target for upper aerodigestive malignancies. Biochim Biophys Acta Rev Cancer 1869:128-137
Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590
Ding, Yuan Chun; Adamson, Aaron W; Steele, Linda et al. (2018) Discovery of mutations in homologous recombination genes in African-American women with breast cancer. Fam Cancer 17:187-195
Kurata, Jessica S; Lin, Ren-Jang (2018) MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs. RNA 24:966-981
Hardwick, Nicola R; Frankel, Paul; Ruel, Christopher et al. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res 24:1315-1325
Dietze, Eric C; Chavez, Tanya A; Seewaldt, Victoria L (2018) Obesity and Triple-Negative Breast Cancer: Disparities, Controversies, and Biology. Am J Pathol 188:280-290
Kingsmore, Kathryn M; Vaccari, Andrea; Abler, Daniel et al. (2018) MRI analysis to map interstitial flow in the brain tumor microenvironment. APL Bioeng 2:
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096

Showing the most recent 10 out of 1396 publications